Guardion Health Sciences Stock (NASDAQ:GHSI)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$3.30

52W Range

$3.04 - $18.00

50D Avg

$9.67

200D Avg

$8.55

Market Cap

$4.17M

Avg Vol (3M)

$113.37K

Beta

0.71

Div Yield

$20.00 (461.54%)

GHSI Company Profile


Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

9

IPO Date

Apr 05, 2019

Website

GHSI Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 18
Vision Testing Diagnotics$609.36K
Corporate Segment-
Medical Foods$332.80K

Fiscal year ends in Dec 23 | Currency in USD

GHSI Financial Summary


Dec 23Dec 22Dec 21
Revenue$12.25M$11.05M$7.23M
Operating Income$-4.34M$432.68K$-10.48M
Net Income$158.03K$-30.28M$-24.75M
EBITDA$-4.34M$1.68M$-9.57M
Basic EPS-$-24.79$-52.23
Diluted EPS-$-24.79$-52.23

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 20Aug 12, 20 | 5:00 PM

Peer Comparison


TickerCompany
AKANAkanda Corp.
BFRIBiofrontera Inc.
QLIQilian International Holding Group Limited
EVOKEvoke Pharma, Inc.
TKNOAlpha Teknova, Inc.
AQSTAquestive Therapeutics, Inc.
LFCRLifecore Biomedical, Inc.
ORGOOrganogenesis Holdings Inc.
UPCUniverse Pharmaceuticals INC
SHPHShuttle Pharmaceuticals Holdings, Inc.
ACRXTalphera, Inc.
PTPIPetros Pharmaceuticals, Inc.
ADMPAdamis Pharmaceuticals Corporation
CYTHCyclo Therapeutics, Inc.
AGRXAgile Therapeutics, Inc.
IMCCIM Cannabis Corp.